Following a full submission
AWMSG advice |
|||
| Status: Not recommended | |||
Histamine dihydrochloride (Ceplene®) is not recommended for use within NHS Wales for maintenance therapy for adult patients with acute myeloid leukaemia in accordance with its licensed indication. The case for clinical effectiveness and cost effectiveness has not been proven. |
|||
|
|||
Medicine details |
|||
| Medicine name | histamine dihydrochloride (Ceplene®) | ||
| Formulation | 0.5 mg/0.5ml solution for injection | ||
| Reference number | 346 | ||
| Indication | Maintenance therapy for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene® has not been fully demonstrated in patients older than age 60 |
||
| Company | Meda Pharmaceuticals Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Not recommended | ||
| Advice number | 0411 | ||
| NMG meeting date | 10/03/2011 | ||
| AWMSG meeting date | 13/04/2011 | ||
| Ratification by Welsh Government | 02/11/2011 | ||
| Date of issue | 02/11/2011 | ||